Month: August 2025

4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Written by Customer Service on August 11, 2025. Posted in Earnings Releases And Operating Results.

4D-150 Phase 3 program in wet AMD advancing ahead of plan, with expected 4FRONT-1 data readout accelerated to H1 2027 from H2 2027 and 4FRONT-2 initiated ahead of schedule Presented positive 60-week results from 4D-150 SPECTRA clinical trial in DME Streamlined organization to drive late-stage execution $417 million in cash, cash equivalents and marketable securities as of June 30, 2025, expected to fund planned operations into 2028 EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported Q2 2025 financial results, provided operational highlights and outlined expected...

ArriVent BioPharma Reports Second Quarter 2025 Financial Results

Written by Customer Service on August 11, 2025. Posted in Earnings Releases And Operating Results.

Positive interim Phase 1b update underscores firmonertinib’s potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll first patient in 2H 2025 Dosed the first patient in the Phase 1 Study for ARR-217 (MRG007), a CDH17 targeted ADC, in gastrointestinal tumors Top-line firmonertinib monotherapy data from global pivotal FURVENT Phase 3 study for first-line EGFR exon20 insertion mutant NSCLC projected to be in early 2026 Cash and investments of $254.5 million as of June 30, 2025, in addition to $81.1 million raised in the public offering in July 2025, expected to fund our operating plan to mid-2027NEWTOWN SQUARE, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) — ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative...

Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

Written by Customer Service on August 11, 2025. Posted in Earnings Releases And Operating Results.

Presentation of interim analysis from approximately 25 six-month evaluable BCG-Unresponsive patients in the ongoing ADVANCED-2 trial expected at a medical conference in 1Q 2026Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support on track for 3Q 2025 On track to provide an interim update from the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients in 4Q 2025Cash, cash equivalents and investments of approximately $146 million as of June 30, 2025, expected to support planned operations into mid-2027NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the second...

Catheter Precision, Inc. Reports Results of Operations for Second Quarter 2025

Written by Customer Service on August 11, 2025. Posted in Earnings Releases And Operating Results.

Revenue Increased 128% Year Over Year and 48% Sequentially FORT MILL, S.C., Aug. 11, 2025 (GLOBE NEWSWIRE) — Catheter Precision, Inc. (VTAK – NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market, today announced its results of operations for the three and six months ended June 30, 2025. Highlights of the second quarter include:Revenue from product sales increased 128% over Q2 2024. First half 2025 revenue increased 103% over first half 2024. Sequential quarter over quarter sales increased 48% The CE Mark for the LockeT product was received during the quarter, with sales expected to start in Europe during the third quarter of this year. Significant clinical data was presented at the annual Heart Rhythm Society symposium, which...

CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Written by Customer Service on August 11, 2025. Posted in Earnings Releases And Operating Results.

Reported 32-week data from Phase 2b RewinD-LB Trial Extension phase showing neflamapimod treatment resulted in a substantial reduction in clinically significant worsening compared to control arm over 32 weeks, which improved further among patients who have minimal evidence of Alzheimer’s disease (AD) co-pathology (ptau181 < 2.2 pg/mL at screening) At week 32 of the Extension phase, patients treated with neflamapimod demonstrated a significant reduction from baseline in plasma levels of glial fibrillary acidic protein (GFAP) Plan to engage with U.S. Food and Drug Administration (FDA) in the fourth quarter of 2025 to align on trial design for the Phase 3 program in Dementia with Lewy Bodies (DLB) BOSTON, Aug. 11, 2025 (GLOBE NEWSWIRE) — CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related...

Dynacor Reports Q2-2025 Results and Advances International Expansion Plan

Written by Customer Service on August 11, 2025. Posted in Earnings Releases And Operating Results.

MONTREAL, Aug. 11, 2025 (GLOBE NEWSWIRE) — Dynacor Group Inc. (TSX: DNG) (“Dynacor” or the “Corporation”) today announced its unaudited financial and operational results1 for the second quarter ended June 30, 2025, and achievement of key milestones for its 2030 international expansion plan. “In the second quarter of 2025, Dynacor achieved important milestones that position us well for the future,” said Jean Martineau, President & CEO. “While advancing work on the pilot plant in Senegal, we carried out positive due diligence for the Svetlana plant in Ecuador and signed an MOU with a partner in Ghana. The acquisition of Svetlana is a particularly important step towards our 2030 goal of reaching $1 billion in sales. At the same time, operations saw an unseasonably soft quarter with ore supply headwinds in the latter months. Given...

FUNDAMENTAL GLOBAL INC. ANNOUNCES TICKER SYMBOL CHANGES EFFECTIVE AUGUST 11, 2025

Written by Customer Service on August 11, 2025. Posted in Public Companies.

Charlotte, NC, Aug. 11, 2025 (GLOBE NEWSWIRE) — Fundamental Global Inc. (Nasdaq: FGF, FGFPP), (the “Company” or “FG Nexus”), today announced that its ticker symbol will change to NASDAQ: FGNX for its Common Stock and NASDAQ: FGNXP for its Series A Preferred Shares, replacing the previous symbols “FGF” and “FGFPP,” respectively, effective at market open, August 11, 2025. “The ticker change, along with our upcoming name change to FG Nexus, reflects our evolution as the premier Ethereum pure-play treasury company and our mission to become the world’s largest corporate holder of ETH,” said Kyle Cerminara, CEO and Chairman of FG Nexus. The ticker changes are part of the Company’s continued transformation following its recent $200 million private placement and $5 billion shelf registration...

Trump Media Files Amended Registration Statement for Bitcoin ETF

Written by Customer Service on August 11, 2025. Posted in Public Companies.

Custodied by Crypto.com, ETF to Launch Later This Year SARASOTA, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) — Trump Media and Technology Group Corp. (Nasdaq, NYSE Texas: DJT) (“Trump Media” or the “Company”), operator of the social media platform Truth Social, the streaming platform Truth+, and the FinTech brand Truth.Fi, announced today the filing with the U.S. Securities and Exchange Commission of the first amendment to the registration statement on Form S-1 (the “Registration Statement”) for the Truth Social Bitcoin ETF, B.T. (“the ETF”). The ETF will hold bitcoin directly and offer its shares (the “Shares”) to investors, aiming to reflect Bitcoin’s price performance. Crypto.com will act as the ETF’s exclusive Bitcoin custodian, prime execution agent and liquidity provider. The launch of the Truth Social Bitcoin ETF is pending effectiveness...

Full Alliance Group’s Qubitera Holdings Expands Quant Blockchain Healthcare Development Roadmap

Written by Customer Service on August 11, 2025. Posted in Public Companies.

Qubitera Holdings Charts Mid-2027 Global Launch for Quantum-Safe EHR/EMR Platform TAMPA, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) — Full Alliance Group, Inc. (OTC: FAGI) announced today that its subsidiary, Qubitera Holdings Inc., has released a comprehensive five-phase technical roadmap to deploy a post-quantum cryptography (PQC)-based Electronic Health Record (EHR) and Electronic Medical Record (EMR) system worldwide by mid-2027. This groundbreaking platform is designed to give patients complete control over their health data—allowing them to grant, revoke, or limit access to their medical records at any time and to receive real-time notifications whenever those records are accessed. Built on blockchain technology with NIST-standardized PQC algorithms—CRYSTALS-Kyber (ML-KEM), CRYSTALS-Dilithium (ML-DSA), and FALCON—it protects medical...

Nexxen Renews and Expands its Strategic Partnership with VIDAA, with a Focus on Growing VIDAA’s North American CTV Footprint

Written by Customer Service on August 11, 2025. Posted in Public Companies.

Agreement extends Nexxen’s global ACR data exclusivity and grants ad monetization exclusivity on VIDAA media in North America through at least the end of 2029 Nexxen investing an additional $35 million in VIDAA to accelerate the expansion of VIDAA’s North American CTV base, ad inventory and ACR data scale NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) — Nexxen International Ltd. (NASDAQ: NEXN) (“Nexxen” or the “Company”), a global, flexible advertising technology platform with deep expertise in data and advanced TV, today announced the renewal and expansion of its long-term strategic partnership with VIDAA, the world’s fastest-growing Connected TV (“CTV”) platform powering tens of millions of CTVs from Hisense, Toshiba and other leading brands globally. Together, the companies will now focus on scaling North American TV distribution...

Month: August 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals